Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Glucagon is a 29-amino-acid pancreatic hormone produced by the alpha cells of the islets of Langerhans. It is the physiological counterpart to insulin and raises blood glucose via hepatic glycogenolysis and gluconeogenesis. It is approved as an emergency treatment for severe hypoglycaemia and as a diagnostic aid; its receptor is also a target of modern dual and triple incretin agonists.
Researched for
Emergency treatment of severe hypoglycaemiaDiagnostic aid (gastrointestinal motility, stimulation tests)Receptor component of dual and triple incretin agonists
Official status
US: Prescription
Approved in the US as a prescription medicine — as injectable glucagon (GlucaGen, Gvoke) and as a nasal powder (Baqsimi) for emergency treatment of severe hypoglycaemia and as a diagnostic aid. Glucagon has been approved in the US since 1960.
Glucagon is produced in the alpha cells of the pancreas (islets of Langerhans) and released when blood sugar is low. Glucagon binds the glucagon receptor (GCGR), a G-protein-coupled receptor expressed predominantly on hepatocytes. Activation stimulates adenylate cyclase, raises cyclic AMP and activates protein kinase A. This drives glycogenolysis (breakdown of hepatic glycogen into glucose) and gluconeogenesis (de novo glucose synthesis), which raises blood glucose. Glucagon also promotes lipolysis. As the counterpart to insulin it contributes to glucose homeostasis. It transiently relaxes gastrointestinal smooth muscle, which is the basis of its diagnostic use in imaging.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
4 observations · 2 tiers
Human RCT
2
Human trial
2
03
What the studies show
Human RCT
Mensch
Rickels MR, Ruedy KJ, Foster NC. et al. 2016
Increase in blood glucose during insulin-induced hypoglycaemia after nasal or parenteral administration
What does NOT follow: Demonstrated in controlled studies in adults with type 1 diabetes; the investigation was conducted under clinical supervision and describes an emergency indication, not self-management.
Human trial
Mensch
Transient relaxation of gastrointestinal smooth muscle, underpinning its use as a diagnostic aid in imaging
What does NOT follow: Established clinical application; the effect is short-lived in keeping with the peptide's very short half-life.
Human trial
Mensch
Yuen KCJ. 2011
Elicitation of a measurable growth-hormone response, used in the glucagon stimulation test to assess growth-hormone deficiency
What does NOT follow: Diagnostic context; cut-off values vary by protocol and patient population (e.g. body weight).
Human RCT
Mensch
Jastreboff AM, Kaplan LM, Frías JP. et al. 2023
Glucagon-receptor activation as one of three receptor components of a triple-agonist drug candidate with observed weight reduction
What does NOT follow: Refers to the investigational agent retatrutide (GLP-1/GIP/glucagon receptor), not native glucagon; phase-2 data, not yet approved.
04
Where studies disagree
Open question
Does glucagon's therapeutic value lie in agonism or antagonism?
POSITION A
Glucagon agonism acutely raises blood glucose (emergency in severe hypoglycemia) — and in dual/triple agonists (survodutide, retatrutide, mazdutide), controlled glucagon agonism increases energy expenditure and lowers liver fat.
POSITION B
Conversely, glucagon-receptor ANTAGONISM (antibodies, small molecules) is being researched to reduce excessive hepatic glucose production in type 2 diabetes.
CURRENT STATE · Both directions are active research fields; which strategy makes sense depends on the therapeutic goal (acute glucose raising, weight/liver effects vs. diabetes control).
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 0.13 h. Pure pharmacokinetic model — not a dosing recommendation.
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Intranasal
Studied as a nasal powder (Baqsimi) in controlled trials and in the marketing authorisation.
Intramuscular
Injectable glucagon (GlucaGen) as the comparator arm in the hypoglycaemia studies.
Subcutaneous
Pre-filled autoinjector (Gvoke) as a subcutaneous form of the emergency treatment.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
⚠ Important — please read
This platform does NOT provide usage or dosing instructions. The points below describe risks and are meant to help avoid harm — they do not replace medical advice. Anyone who uses a substance should discuss it with a doctor.
This substance is approved (in at least one country) — use belongs in medical hands, within the approved indication and a physician-set dose.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human RCT
Nausea and vomiting
Frequently reported in studies of glucagon products; usually transient. With nasal administration, local upper-airway irritation has additionally been described.
häufig dokumentiert
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
08
Risks & hygiene aspects in the literature
What regulatory and scientific literature reports on risks, sterility and identity in non-pharmaceutical sources — descriptive, not a hygiene guide.
Contraindications in hormone-producing tumours
Prescribing information lists phaeochromocytoma, insulinoma and glucagonoma as contraindications or caution areas, because glucagon may trigger dangerous blood-pressure or blood-glucose reactions there.
09
Regulatory voices
Direct statements from official assessment documents — paraphrased with date and source link.
FDAU.S. Food and Drug Administration
2019-07-24
FDA announcement on the approval of Baqsimi (2019) — the first non-injectable glucagon product for emergency treatment of severe hypoglycaemia.
Baqsimi is indicated for the treatment of severe hypoglycaemia in patients with diabetes ages one year and older and is the first approved glucagon therapy that can be administered without an injection.
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
Under search terms like 'anti-glucagon' or 'glucagon antibody', blocking the glucagon receptor is discussed as a diabetes approach.
research/professional interest
Not supported by studies: Glucagon antagonists are largely experimental; several programs were halted over liver-enzyme rises and lipid effects. No approved glucagon-antagonist drug for broad use.
11
Legal status by country
Country
Status
Note
Checked
United States
Prescription
Approved in the US as a prescription medicine — as injectable glucagon (GlucaGen, Gvoke) and as a nasal powder (Baqsimi) for emergency treatment of severe hypoglycaemia and as a diagnostic aid. Glucagon has been approved in the US since 1960.
2026-06-07
Germany
Prescription
Prescription-only in Germany. GlucaGen is authorised via EMA or national procedures; the nasal powder Baqsimi received an EU authorisation in 2019. Used for emergency treatment of severe hypoglycaemia and as a diagnostic aid.
2026-06-07
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.